Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

UK ENcorafenib and BInimetinib Real-world Study in Melanoma

UK ENcorafenib and BInimetinib Real-world Study in Melanoma (UK-EnBiRiM): A Prospective Observational Real-world App-based Study to Explore HRQoL Outcomes, of Adults With Metastatic Cutaneous BRAF V600 Mutation-positive Melanoma, Initiated on Combination Encorafenib and Binimetinib Therapy in the UK

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is a prospective longitudinal multi-centre observational study conducted in the United Kingdom, in patients with metastatic cutaneous BRAF V600 mutation-positive melanoma assigned to receive encorafenib and binimetinib. The aim of this study is to learn about how encorafenib and binimetinib perform, patients' experiences of using them, and how they might affect patient's quality of life, in the real world, when these treatments are prescribed by doctors instead of in a clinical trial. Participants will complete electronic data entry via questionnaires over a 24-month period. Site research teams will also complete electronic data entry using participants' medical records over a 24-month period.

Who May Be Eligible (Plain English)

Who May Qualify: - Aged 18 years or older - Willing and capable of providing written willing to sign a consent form - Access to a smartphone - Diagnosis of metastatic cutaneous melanoma with presence of BRAF V600 mutation in tumour tissue prior to enrolment - Clinical decision has been made to begin encorafenib plus binimetinib treatment in accordance with current Summary of Product Characteristics - Encorafenib plus binimetinib to be prescribed as second-line treatment for BRAF V600-mutant metastatic melanoma Who Should NOT Join This Trial: - Patients receiving systemic treatment for any tumours other than melanoma - Patients participating in a clinical trial Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion criteria: * Aged 18 years or older * Willing and capable of providing written informed consent * Access to a smartphone * Diagnosis of metastatic cutaneous melanoma with presence of BRAF V600 mutation in tumour tissue prior to enrolment * Clinical decision has been made to begin encorafenib plus binimetinib treatment in accordance with current Summary of Product Characteristics * Encorafenib plus binimetinib to be prescribed as second-line treatment for BRAF V600-mutant metastatic melanoma Exclusion criteria: * Patients receiving systemic treatment for any tumours other than melanoma * Patients participating in a clinical trial

Treatments Being Tested

BIOLOGICAL

Encorafenib + Binimetinib

Participants will have received a clinical decision to begin encorafenib plus binimetinib treatment as a second-line treatment for metastatic melanoma, in accordance with current Summary of Product Characteristics

Locations (7)

Southend University Hospital
Westcliff-on-Sea, Essex, United Kingdom
Queen Elizabeth Hospital
Birmingham, United Kingdom
Addenbrookes Hospital
Cambridge, United Kingdom
University Hospital Coventry and Warwickshire
Coventry, United Kingdom
Royal Marsden Hospital
London, United Kingdom
Royal Preston Hospital
Preston, United Kingdom
Southampton General Hospital
Southampton, United Kingdom